RYTM Stock Earnings Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
RYTM Stock | USD 57.74 0.33 0.57% |
About 52% of Rhythm Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Rhythm Pharmaceuticals suggests that many traders are impartial. Rhythm Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Rhythm Pharmaceuticals. Many technical investors use Rhythm Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Rhythm |
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Read at investorplace.com
Rhythm Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
48
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Rhythm Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Rhythm Pharmaceuticals.
News SentimentNeutral | Hype SentimentNeutral | Insider SentimentDisposing |
Rhythm Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Rhythm Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rhythm Pharmaceuticals Fundamental Analysis
We analyze Rhythm Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rhythm Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rhythm Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Rhythm Pharmaceuticals is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Rhythm Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rhythm Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rhythm Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rhythm Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Rhythm Pharmaceuticals Related Equities
QURE | Uniqure NV | 109.59 | ||||
INZY | Inozyme Pharma | 9.56 | ||||
PTGX | Protagonist Therapeutics | 2.72 | ||||
BDTX | Black Diamond | 2.09 | ||||
RVMD | Revolution Medicines | 0.53 | ||||
KNSA | Kiniksa Pharmaceuticals | 0.42 | ||||
ACLX | Arcellx | 0.82 | ||||
VRDN | Viridian Therapeutics | 0.87 | ||||
NUVL | Nuvalent | 1.01 | ||||
SLDB | Solid Biosciences | 1.17 | ||||
CGEM | Cullinan Oncology | 1.18 | ||||
AKRO | Akero Therapeutics | 1.54 | ||||
ARVN | Arvinas | 1.95 | ||||
RNA | Avidity Biosciences | 2.04 | ||||
PLRX | Pliant Therapeutics | 2.22 | ||||
RCKT | Rocket Pharmaceuticals | 2.38 | ||||
MGTX | MeiraGTx Holdings | 3.40 | ||||
STOK | Stoke Therapeutics | 3.63 | ||||
SNDX | Syndax Pharmaceuticals | 3.98 | ||||
RLAY | Relay Therapeutics | 5.74 | ||||
VTYX | Ventyx Biosciences | 7.64 |
Check out Rhythm Pharmaceuticals Hype Analysis, Rhythm Pharmaceuticals Correlation and Rhythm Pharmaceuticals Performance. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.